Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicentric, Double-blind, Randomised Controled Trial of Hyperbaric-oxygen Therapy (HBOT) Versus Placebo for Treating Vaso-Occlusive Crisis (VOC) in Sickle Cell Disease (SCD) After 8 Years Old

NCT05289700 is registered in ClinicalTrials.gov with University Hospital, Geneva as lead sponsor.

NCT NCT05289700
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05289700 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicentric, Double-blind, Randomised Controled Trial of Hyperbaric-oxygen Therapy (HBOT) Versus Placebo for Treating Vaso-Occlusive Crisis (VOC) in Sickle Cell Disease (SCD) After 8 Years Old
Lead sponsor
University Hospital, Geneva
Phase
Phase 3
Overall status
Unknown status
Start date
September 15, 2022
Completion date
March 31, 2025
Enrollment
100 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hyperbaric oxygen therapy, sickle cell disease, vaso-occlusive crisis